ALTOMONTE, MARESA
ALTOMONTE, MARESA
Biology and clinical applications of CD40 in cancer treatment
2010-01-01 Fonsatti, E; Maio, M; Altomonte, M; Hersey, P
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893
2010-01-01 Kalbasi, A; Fonsatti, E; Natali, Pg; Altomonte, M; Bertocci, E; Cutaia, O; Calabrò, L; Chiou, M; Tap, W; Chmielowski, B; Maio, M; Ribas, A.
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients
2010-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
2013-01-01 Altomonte, M; DI GIACOMO, ANNA MARIA; Queirolo, P; Ascierto, Pa; Spagnolo, F; Bajetta, E; Calabrò, L; Danielli, R; de Rosa, F; Maur, M; Chiarion-Sileni, V; Ferrucci, Pf; Giannarelli, D; Testori, A; Ridolfi, R; Maio, M
Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort
2014-01-01 Ascierto, P. A.; Simeone, E.; Sileni, V. C.; Pigozzo, J.; Maio, M.; Altomonte, M.; Del Vecchio, M.; Di Guardo, L.; Marchetti, P.; Ridolfi, R.; Cognetti, F.; Testori, A.; Bernengo, M. G.; Guida, M.; Marconcini, R.; Mandala, M.; Cimminiello, C.; Rinaldi, G.; Aglietta, M.; Queirolo, P.
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study
2015-01-01 Calabro, L.; Morra, A.; Fonsatti, E.; Cutaia, O.; Fazio, C.; Annesi, D.; Lenoci, M.; Amato, G.; Danielli, R.; Altomonte, M.; Giannarelli, D.; Di Giacomo, A. M.; Maio, M.
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma
2010-01-01 Fratta, E; Sigalotti, L; Colizzi, F; Covre, A; Nicolay, Hj; Danielli, R; Fonsatti, E; Altomonte, M; Calabrò, L; Coral, S; Maio, M
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016
2018-01-01 Russo, V.; Chiarucci, C.; Lofiego, M. F.; Fazio, C.; Bertocci, E.; Cutaia, O.; Giacobini, G.; Lazzeri, A.; Lamboglia, Antonello; Altomonte, M.; Tunici, P.; Covre, A.; Maio, M.
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
2020-01-01 Maio, M.; Hamid, O.; Larkin, J.; Covre, A.; Altomonte, M.; Calabro, L.; Vardhana, S. A.; Robert, C.; Ibrahim, R.; Anichini, A.; Wolchok, J. D.; Di Giacomo, A. M.
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
2011-01-01 Di Giacomo, Anna Maria; Danielli, Riccardo; Calabrò, Luana; Bertocci, Erica; Nannicini, Chiara; Giannarelli, Diana; Balestrazzi, Angelo; Vigni, Francesco; Riversi, Valentina; Miracco, Clelia; Biagioli, Maurizio; Altomonte, Maresa; Maio, Michele
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients
2009-01-01 Di Giacomo, A; Danielli, R; Calabrò, L; Guidoboni, M; Miracco, C; Biagioli, M; Mazzei, M; Altomonte, Maresa; Maio, M
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients
2009-01-01 DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients
2009-01-01 Di Giacomo, A. M.; Danielli, R.; Calabro, L.; Bertocci, E.; Nannicini, C.; Miracco, C.; Biagioli, M.; Mazzei, M. A.; Altomonte, M.; Maio, M.
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy
2018-01-01 Danielli, Riccardo; Cisternino, Filomena; Giannarelli, Diana; Calabrò, Luana; Camerini, Roberto; Savelli, Vinno; Bova, Giovanni; Dragonetti, Rosella; Di Giacomo, Anna Maria; Altomonte, Maresa; Maio, Michele
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
2013-01-01 Di Giacomo, Anna Maria; Calabrò, Luana; Danielli, Riccardo; Fonsatti, Ester; Bertocci, Erica; Pesce, Isabella; Fazio, Carolina; Cutaia, Ornella; Giannarelli, Diana; Miracco, Clelia; Biagioli, Maurizio; Altomonte, Maresa; Maio, Michele
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments?
2007-01-01 Calabrò, L.; DI GIACOMO, A. M.; Altomonte, M.; Fonsatti, E.; Mazzei, M. A.; Volterrani, L.; Miracco, C.; Maio, M.
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours
2010-01-01 Fonsatti, E; Nicolay, Hj; Altomonte, M; Covre, A; Maio, M
THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS
2009-01-01 Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
2018-01-01 Calabro, L.; Morra, A.; Giannarelli, D.; Amato, G.; D'Incecco, A.; Covre, A.; Lewis, A.; Rebelatto, M. C.; Danielli, R.; Altomonte, M.; Di Giacomo, A. M.; Maio, M.
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
2021-01-01 Calabro, L.; Rossi, G.; Morra, A.; Rosati, C.; Cutaia, O.; Daffina, M. G.; Altomonte, M.; Di Giacomo, A. M.; Casula, M.; Fazio, C.; Palmieri, G.; Giannarelli, D.; Covre, A.; Maio, M.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Biology and clinical applications of CD40 in cancer treatment | 1-gen-2010 | Fonsatti, E; Maio, M; Altomonte, M; Hersey, P | - | |
| CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 | 1-gen-2010 | Kalbasi, A; Fonsatti, E; Natali, Pg; Altomonte, M; Bertocci, E; Cutaia, O; Calabrò, L; Chiou, M; Tap, W; Chmielowski, B; Maio, M; Ribas, A. | - | |
| Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients | 1-gen-2010 | Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M | - | |
| Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme | 1-gen-2013 | Altomonte, M; DI GIACOMO, ANNA MARIA; Queirolo, P; Ascierto, Pa; Spagnolo, F; Bajetta, E; Calabrò, L; Danielli, R; de Rosa, F; Maur, M; Chiarion-Sileni, V; Ferrucci, Pf; Giannarelli, D; Testori, A; Ridolfi, R; Maio, M | - | |
| Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort | 1-gen-2014 | Ascierto, P. A.; Simeone, E.; Sileni, V. C.; Pigozzo, J.; Maio, M.; Altomonte, M.; Del Vecchio, M.; Di Guardo, L.; Marchetti, P.; Ridolfi, R.; Cognetti, F.; Testori, A.; Bernengo, M. G.; Guida, M.; Marconcini, R.; Mandala, M.; Cimminiello, C.; Rinaldi, G.; Aglietta, M.; Queirolo, P. | - | |
| Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study | 1-gen-2015 | Calabro, L.; Morra, A.; Fonsatti, E.; Cutaia, O.; Fazio, C.; Annesi, D.; Lenoci, M.; Amato, G.; Danielli, R.; Altomonte, M.; Giannarelli, D.; Di Giacomo, A. M.; Maio, M. | - | |
| Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma | 1-gen-2010 | Fratta, E; Sigalotti, L; Colizzi, F; Covre, A; Nicolay, Hj; Danielli, R; Fonsatti, E; Altomonte, M; Calabrò, L; Coral, S; Maio, M | - | |
| Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 | 1-gen-2018 | Russo, V.; Chiarucci, C.; Lofiego, M. F.; Fazio, C.; Bertocci, E.; Cutaia, O.; Giacobini, G.; Lazzeri, A.; Lamboglia, Antonello; Altomonte, M.; Tunici, P.; Covre, A.; Maio, M. | - | |
| Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era | 1-gen-2020 | Maio, M.; Hamid, O.; Larkin, J.; Covre, A.; Altomonte, M.; Calabro, L.; Vardhana, S. A.; Robert, C.; Ibrahim, R.; Anichini, A.; Wolchok, J. D.; Di Giacomo, A. M. | - | |
| Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) | 1-gen-2011 | Di Giacomo, Anna Maria; Danielli, Riccardo; Calabrò, Luana; Bertocci, Erica; Nannicini, Chiara; Giannarelli, Diana; Balestrazzi, Angelo; Vigni, Francesco; Riversi, Valentina; Miracco, Clelia; Biagioli, Maurizio; Altomonte, Maresa; Maio, Michele | - | |
| Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients | 1-gen-2009 | Di Giacomo, A; Danielli, R; Calabrò, L; Guidoboni, M; Miracco, C; Biagioli, M; Mazzei, M; Altomonte, Maresa; Maio, M | - | |
| Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients | 1-gen-2009 | DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M | - | |
| Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients | 1-gen-2009 | Di Giacomo, A. M.; Danielli, R.; Calabro, L.; Bertocci, E.; Nannicini, C.; Miracco, C.; Biagioli, M.; Mazzei, M. A.; Altomonte, M.; Maio, M. | - | |
| Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy | 1-gen-2018 | Danielli, Riccardo; Cisternino, Filomena; Giannarelli, Diana; Calabrò, Luana; Camerini, Roberto; Savelli, Vinno; Bova, Giovanni; Dragonetti, Rosella; Di Giacomo, Anna Maria; Altomonte, Maresa; Maio, Michele | - | |
| Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme | 1-gen-2013 | Di Giacomo, Anna Maria; Calabrò, Luana; Danielli, Riccardo; Fonsatti, Ester; Bertocci, Erica; Pesce, Isabella; Fazio, Carolina; Cutaia, Ornella; Giannarelli, Diana; Miracco, Clelia; Biagioli, Maurizio; Altomonte, Maresa; Maio, Michele | - | |
| Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? | 1-gen-2007 | Calabrò, L.; DI GIACOMO, A. M.; Altomonte, M.; Fonsatti, E.; Mazzei, M. A.; Volterrani, L.; Miracco, C.; Maio, M. | - | |
| Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours | 1-gen-2010 | Fonsatti, E; Nicolay, Hj; Altomonte, M; Covre, A; Maio, M | - | |
| THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS | 1-gen-2009 | Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M | - | |
| Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study | 1-gen-2018 | Calabro, L.; Morra, A.; Giannarelli, D.; Amato, G.; D'Incecco, A.; Covre, A.; Lewis, A.; Rebelatto, M. C.; Danielli, R.; Altomonte, M.; Di Giacomo, A. M.; Maio, M. | - | |
| Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study | 1-gen-2021 | Calabro, L.; Rossi, G.; Morra, A.; Rosati, C.; Cutaia, O.; Daffina, M. G.; Altomonte, M.; Di Giacomo, A. M.; Casula, M.; Fazio, C.; Palmieri, G.; Giannarelli, D.; Covre, A.; Maio, M. | - |